Peak Bio, Inc. filed its Annual on Jun 17, 2022 for the period ending Dec 31, 2021. In this report its auditor, Mayer Hoffman McCann P.C., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0086 USD | 0.00% | 0.00% | -95.41% |
03-05 | Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. | CI |
02-16 | Peak Bio, Inc. announced that it has received $2.238 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-95.41% | 199K | |
+52.36% | 58.06B | |
-3.86% | 40.53B | |
+36.84% | 38.99B | |
-12.01% | 26.56B | |
+14.13% | 26.7B | |
-21.62% | 18.98B | |
+0.21% | 12.17B | |
+25.96% | 11.92B | |
+23.02% | 12B |
- Stock Market
- Equities
- PKBO Stock
- News Peak Bio, Inc.
- Peak Bio, Inc. Auditor Raises 'Going Concern' Doubt